Loading market dashboard
HUTCHMED (China) Limited
HCMHealthcareNASDAQHK
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m.
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study
HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership
HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations
Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California.
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) has been assigned an average recommendation of "Hold" from the six brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma (“DLBCL”) in China. The first patient received the first dose on March 20, 2026.
OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom”), a leading provider of comprehensive, cloud‑based human capital management software, today announced it has received the H3 HR Advisors HCM Technology Signal Award for workforce change. This award recognizes Paycom's consistent impact through innovations such as decisioning logic and automation across its HR and payroll software, which help organizations navigate significant transformation. “Organizations don't need m.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc. (“Epizyme”), an Ipsen (“Ipsen”) company, in China. Epizyme is the Marketing Authorization Holder of TAZVERIK® in the Chinese mainland, for which HUTCHMED Limited (a subsidiary of the Company) acts as the domestic agent/licensee. Ipsen has informed HUTCHMED that it is voluntarily withdrawing TAZVERIK® in the US. As a result, steps have been taken to initiate the market withdrawal and product recall in China. Consequently, HUTCHMED Limited has initiated a withdrawal and product recall from the Chinese mainland, Hong Kong and Macau, and is discontinuing all active tazemetostat clinical trials. Existing patients should consult their treating physicians immediately to discuss their treatment options.
HUTCHMED (NASDAQ: HCM) management used its 2025 annual results call to highlight growth in global sales for FRUZAQLA, a rebound in China market performance in the second half, and increasing investment behind its ATTC (antibody-targeted therapy conjugate) platform as it advances multiple assets into clinical development. 2025 highlights: overseas growth for FRUZAQLA and a second-half rebound
